Early data on NextCure's immuno-oncology drug in lung cancer patients delights investors
Shares of freshly public biotech NextCure skyrocketed on Tuesday after the company published an abstract highlighting initial data from an early-stage study of its sole …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
